Future studies should test FadA–cadherin blockade for barrier and endothelial protection, Fap2–TIGIT antagonism to enhance anti-tumor immunity, and strain-specific phage therapies with mucoadhesive delivery, alongside nutrition-anchored trials targeting NETosis, epithelial lipidome and TLR signaling, and multi-matrix surveillance to pre-empt flares, treatment failure and vascular events [136,137,138]. Here, TIGIT is linked to neoplasm.